These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 22443199)

  • 21. Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers.
    Kuchenbaecker KB; Neuhausen SL; Robson M; Barrowdale D; McGuffog L; Mulligan AM; Andrulis IL; Spurdle AB; Schmidt MK; Schmutzler RK; Engel C; Wappenschmidt B; Nevanlinna H; Thomassen M; Southey M; Radice P; Ramus SJ; Domchek SM; Nathanson KL; Lee A; Healey S; Nussbaum RL; Rebbeck TR; Arun BK; James P; Karlan BY; Lester J; Cass I; ; Terry MB; Daly MB; Goldgar DE; Buys SS; Janavicius R; Tihomirova L; Tung N; Dorfling CM; van Rensburg EJ; Steele L; v O Hansen T; Ejlertsen B; Gerdes AM; Nielsen FC; Dennis J; Cunningham J; Hart S; Slager S; Osorio A; Benitez J; Duran M; Weitzel JN; Tafur I; Hander M; Peterlongo P; Manoukian S; Peissel B; Roversi G; Scuvera G; Bonanni B; Mariani P; Volorio S; Dolcetti R; Varesco L; Papi L; Tibiletti MG; Giannini G; Fostira F; Konstantopoulou I; Garber J; Hamann U; Donaldson A; Brewer C; Foo C; Evans DG; Frost D; Eccles D; ; Douglas F; Brady A; Cook J; Tischkowitz M; Adlard J; Barwell J; Ong KR; Walker L; Izatt L; Side LE; Kennedy MJ; Rogers MT; Porteous ME; Morrison PJ; Platte R; Eeles R; Davidson R; Hodgson S; Ellis S; Godwin AK; Rhiem K; Meindl A; Ditsch N; Arnold N; Plendl H; Niederacher D; Sutter C; Steinemann D; Bogdanova-Markov N; Kast K; Varon-Mateeva R; Wang-Gohrke S; Gehrig A; Markiefka B; Buecher B; Lefol C; Stoppa-Lyonnet D; Rouleau E; Prieur F; Damiola F; ; Barjhoux L; Faivre L; Longy M; Sevenet N; Sinilnikova OM; Mazoyer S; Bonadona V; Caux-Moncoutier V; Isaacs C; Van Maerken T; Claes K; Piedmonte M; Andrews L; Hays J; Rodriguez GC; Caldes T; de la Hoya M; Khan S; Hogervorst FB; Aalfs CM; de Lange JL; Meijers-Heijboer HE; van der Hout AH; Wijnen JT; van Roozendaal KE; Mensenkamp AR; van den Ouweland AM; van Deurzen CH; van der Luijt RB; ; Olah E; Diez O; Lazaro C; Blanco I; Teulé A; Menendez M; Jakubowska A; Lubinski J; Cybulski C; Gronwald J; Jaworska-Bieniek K; Durda K; Arason A; Maugard C; Soucy P; Montagna M; Agata S; Teixeira MR; ; Olswold C; Lindor N; Pankratz VS; Hallberg E; Wang X; Szabo CI; Vijai J; Jacobs L; Corines M; Lincoln A; Berger A; Fink-Retter A; Singer CF; Rappaport C; Kaulich DG; Pfeiler G; Tea MK; Phelan CM; Mai PL; Greene MH; Rennert G; Imyanitov EN; Glendon G; Toland AE; Bojesen A; Pedersen IS; Jensen UB; Caligo MA; Friedman E; Berger R; Laitman Y; Rantala J; Arver B; Loman N; Borg A; Ehrencrona H; Olopade OI; Simard J; Easton DF; Chenevix-Trench G; Offit K; Couch FJ; Antoniou AC;
    Breast Cancer Res; 2014 Dec; 16(6):3416. PubMed ID: 25919761
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Penetrance estimates for BRCA1 and BRCA2 based on genetic testing in a Clinical Cancer Genetics service setting: risks of breast/ovarian cancer quoted should reflect the cancer burden in the family.
    Evans DG; Shenton A; Woodward E; Lalloo F; Howell A; Maher ER
    BMC Cancer; 2008 May; 8():155. PubMed ID: 18513387
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers.
    Rebbeck TR; Kauff ND; Domchek SM
    J Natl Cancer Inst; 2009 Jan; 101(2):80-7. PubMed ID: 19141781
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
    Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
    Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA).
    Mavaddat N; Barrowdale D; Andrulis IL; Domchek SM; Eccles D; Nevanlinna H; Ramus SJ; Spurdle A; Robson M; Sherman M; Mulligan AM; Couch FJ; Engel C; McGuffog L; Healey S; Sinilnikova OM; Southey MC; Terry MB; Goldgar D; O'Malley F; John EM; Janavicius R; Tihomirova L; Hansen TV; Nielsen FC; Osorio A; Stavropoulou A; Benítez J; Manoukian S; Peissel B; Barile M; Volorio S; Pasini B; Dolcetti R; Putignano AL; Ottini L; Radice P; Hamann U; Rashid MU; Hogervorst FB; Kriege M; van der Luijt RB; ; Peock S; Frost D; Evans DG; Brewer C; Walker L; Rogers MT; Side LE; Houghton C; ; Weaver J; Godwin AK; Schmutzler RK; Wappenschmidt B; Meindl A; Kast K; Arnold N; Niederacher D; Sutter C; Deissler H; Gadzicki D; Preisler-Adams S; Varon-Mateeva R; Schönbuchner I; Gevensleben H; Stoppa-Lyonnet D; Belotti M; Barjhoux L; ; Isaacs C; Peshkin BN; Caldes T; de la Hoya M; Cañadas C; Heikkinen T; Heikkilä P; Aittomäki K; Blanco I; Lazaro C; Brunet J; Agnarsson BA; Arason A; Barkardottir RB; Dumont M; Simard J; Montagna M; Agata S; D'Andrea E; Yan M; Fox S; ; Rebbeck TR; Rubinstein W; Tung N; Garber JE; Wang X; Fredericksen Z; Pankratz VS; Lindor NM; Szabo C; Offit K; Sakr R; Gaudet MM; Singer CF; Tea MK; Rappaport C; Mai PL; Greene MH; Sokolenko A; Imyanitov E; Toland AE; Senter L; Sweet K; Thomassen M; Gerdes AM; Kruse T; Caligo M; Aretini P; Rantala J; von Wachenfeld A; Henriksson K; ; Steele L; Neuhausen SL; Nussbaum R; Beattie M; Odunsi K; Sucheston L; Gayther SA; Nathanson K; Gross J; Walsh C; Karlan B; Chenevix-Trench G; Easton DF; Antoniou AC;
    Cancer Epidemiol Biomarkers Prev; 2012 Jan; 21(1):134-47. PubMed ID: 22144499
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain.
    Milne RL; Osorio A; Cajal TR; Vega A; Llort G; de la Hoya M; Díez O; Alonso MC; Lazaro C; Blanco I; Sánchez-de-Abajo A; Caldés T; Blanco A; Graña B; Durán M; Velasco E; Chirivella I; Cardeñosa EE; Tejada MI; Beristain E; Miramar MD; Calvo MT; Martínez E; Guillén C; Salazar R; San Román C; Antoniou AC; Urioste M; Benítez J
    Clin Cancer Res; 2008 May; 14(9):2861-9. PubMed ID: 18451254
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Variation in breast cancer risk in BRCA1 and BRCA2 mutation carriers.
    Rebbeck TR; Domchek SM
    Breast Cancer Res; 2008; 10(4):108. PubMed ID: 18710587
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
    Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
    Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2.
    King MC; Marks JH; Mandell JB;
    Science; 2003 Oct; 302(5645):643-6. PubMed ID: 14576434
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores.
    Lecarpentier J; Silvestri V; Kuchenbaecker KB; Barrowdale D; Dennis J; McGuffog L; Soucy P; Leslie G; Rizzolo P; Navazio AS; Valentini V; Zelli V; Lee A; Amin Al Olama A; Tyrer JP; Southey M; John EM; Conner TA; Goldgar DE; Buys SS; Janavicius R; Steele L; Ding YC; Neuhausen SL; Hansen TVO; Osorio A; Weitzel JN; Toss A; Medici V; Cortesi L; Zanna I; Palli D; Radice P; Manoukian S; Peissel B; Azzollini J; Viel A; Cini G; Damante G; Tommasi S; Peterlongo P; Fostira F; Hamann U; Evans DG; Henderson A; Brewer C; Eccles D; Cook J; Ong KR; Walker L; Side LE; Porteous ME; Davidson R; Hodgson S; Frost D; Adlard J; Izatt L; Eeles R; Ellis S; Tischkowitz M; ; Godwin AK; Meindl A; Gehrig A; Dworniczak B; Sutter C; Engel C; Niederacher D; Steinemann D; Hahnen E; Hauke J; Rhiem K; Kast K; Arnold N; Ditsch N; Wang-Gohrke S; Wappenschmidt B; Wand D; Lasset C; Stoppa-Lyonnet D; Belotti M; Damiola F; Barjhoux L; Mazoyer S; ; Van Heetvelde M; Poppe B; De Leeneer K; Claes KBM; de la Hoya M; Garcia-Barberan V; Caldes T; Perez Segura P; Kiiski JI; Aittomäki K; Khan S; Nevanlinna H; van Asperen CJ; ; Vaszko T; Kasler M; Olah E; Balmaña J; Gutiérrez-Enríquez S; Diez O; Teulé A; Izquierdo A; Darder E; Brunet J; Del Valle J; Feliubadalo L; Pujana MA; Lazaro C; Arason A; Agnarsson BA; Johannsson OT; Barkardottir RB; Alducci E; Tognazzo S; Montagna M; Teixeira MR; Pinto P; Spurdle AB; Holland H; ; Lee JW; Lee MH; Lee J; Kim SW; Kang E; Kim Z; Sharma P; Rebbeck TR; Vijai J; Robson M; Lincoln A; Musinsky J; Gaddam P; Tan YY; Berger A; Singer CF; Loud JT; Greene MH; Mulligan AM; Glendon G; Andrulis IL; Toland AE; Senter L; Bojesen A; Nielsen HR; Skytte AB; Sunde L; Jensen UB; Pedersen IS; Krogh L; Kruse TA; Caligo MA; Yoon SY; Teo SH; von Wachenfeldt A; Huo D; Nielsen SM; Olopade OI; Nathanson KL; Domchek SM; Lorenchick C; Jankowitz RC; Campbell I; James P; Mitchell G; Orr N; Park SK; Thomassen M; Offit K; Couch FJ; Simard J; Easton DF; Chenevix-Trench G; Schmutzler RK; Antoniou AC; Ottini L
    J Clin Oncol; 2017 Jul; 35(20):2240-2250. PubMed ID: 28448241
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early-onset breast cancer.
    Loman N; Johannsson O; Kristoffersson U; Olsson H; Borg A
    J Natl Cancer Inst; 2001 Aug; 93(16):1215-23. PubMed ID: 11504767
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Breast cancer risk in BRCA1 and BRCA2 mutation carriers and polyglutamine repeat length in the AIB1 gene.
    Hughes DJ; Ginolhac SM; Coupier I; Barjhoux L; Gaborieau V; Bressac-de-Paillerets B; Chompret A; Bignon YJ; Uhrhammer N; Lasset C; Giraud S; Sobol H; Hardouin A; Berthet P; Peyrat JP; Fournier J; Nogues C; Lidereau R; Muller D; Fricker JP; Longy M; Toulas C; Guimbaud R; Yannoukakos D; Mazoyer S; Lynch HT; Lenoir GM; Goldgar DE; Stoppa-Lyonnet D; Sinilnikova OM
    Int J Cancer; 2005 Nov; 117(2):230-3. PubMed ID: 15900600
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular characterization and clinical interpretation of BRCA1/BRCA2 variants in families from Murcia (south-eastern Spain) with hereditary breast and ovarian cancer: clinical-pathological features in BRCA carriers and non-carriers.
    Gabaldó Barrios X; Sarabia Meseguer MD; Marín Vera M; Sánchez Bermúdez AI; Macías Cerrolaza JA; Sánchez Henarejos P; Zafra Poves M; García Hernández MR; Cuevas Tortosa E; Aliaga Baño Á; Castillo Guardiola V; Martínez Hernández P; Tovar Zapata I; Martínez Barba E; Ayala de la Peña F; Alonso Romero JL; Noguera Velasco JA; Ruiz Espejo F
    Fam Cancer; 2017 Oct; 16(4):477-489. PubMed ID: 28477318
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer.
    Risch HA; McLaughlin JR; Cole DE; Rosen B; Bradley L; Kwan E; Jack E; Vesprini DJ; Kuperstein G; Abrahamson JL; Fan I; Wong B; Narod SA
    Am J Hum Genet; 2001 Mar; 68(3):700-10. PubMed ID: 11179017
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families.
    Antoniou AC; Durocher F; Smith P; Simard J; Easton DF;
    Breast Cancer Res; 2006; 8(1):R3. PubMed ID: 16417652
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cancer risks in carriers of the BRCA1/2 Ashkenazi founder mutations.
    Kadouri L; Hubert A; Rotenberg Y; Hamburger T; Sagi M; Nechushtan C; Abeliovich D; Peretz T
    J Med Genet; 2007 Jul; 44(7):467-71. PubMed ID: 17307836
    [TBL] [Abstract][Full Text] [Related]  

  • 37. When to Consider Risk-Reducing Mastectomy in BRCA1/BRCA2 Mutation Carriers with Advanced Stage Ovarian Cancer: a Case Study Illustrating the Genetic Counseling Challenges.
    Speight B; Tischkowitz M
    J Genet Couns; 2017 Dec; 26(6):1173-1178. PubMed ID: 28780755
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews.
    Struewing JP; Hartge P; Wacholder S; Baker SM; Berlin M; McAdams M; Timmerman MM; Brody LC; Tucker MA
    N Engl J Med; 1997 May; 336(20):1401-8. PubMed ID: 9145676
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis of cancer risk and BRCA1 and BRCA2 mutation prevalence in the kConFab familial breast cancer resource.
    Mann GJ; Thorne H; Balleine RL; Butow PN; Clarke CL; Edkins E; Evans GM; Fereday S; Haan E; Gattas M; Giles GG; Goldblatt J; Hopper JL; Kirk J; Leary JA; Lindeman G; Niedermayr E; Phillips KA; Picken S; Pupo GM; Saunders C; Scott CL; Spurdle AB; Suthers G; Tucker K; Chenevix-Trench G;
    Breast Cancer Res; 2006; 8(1):R12. PubMed ID: 16507150
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BRCA1 and BRCA2 genetic testing in Italian breast and/or ovarian cancer families: mutation spectrum and prevalence and analysis of mutation prediction models.
    Capalbo C; Ricevuto E; Vestri A; Ristori E; Sidoni T; Buffone O; Adamo B; Cortesi E; Marchetti P; Scambia G; Tomao S; Rinaldi C; Zani M; Ferraro S; Frati L; Screpanti I; Gulino A; Giannini G
    Ann Oncol; 2006 Jun; 17 Suppl 7():vii34-40. PubMed ID: 16760289
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.